Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2008-12-29 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Trading Halt - Amended 1 page ?Kb
Regulatory Filings
2008-12-29 English
Change in substantial holding from UXC 8 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and is described as a 'Notice of change of interests of substantial holder' under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial shareholder group (UXC and related entities) in Ingena Group Limited. The content includes specifics about shareholdings, changes in relevant interests, and annexures listing entities and changes. This type of filing is a notification of changes in major shareholding levels, consistent with regulatory requirements for substantial holders to disclose changes in their ownership stakes. It is not a financial report, earnings release, or management discussion, but a formal notification of shareholding changes.
2008-12-23 English
CAP Correction: Incorrect ASX Code - should be IGG 1
Regulatory Filings
2008-12-23 English
AGM Presentation 22 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'AGM PRESENTATION' and explicitly states it is a presentation given to shareholders at the 2008 Annual General Meeting of Imugene Limited. The content includes detailed slides about the company's vaccine development, trial results, patents, management, and strategy, which are typical of a presentation format rather than a formal report. The document is not a full annual report or financial statement but a presentation delivered at the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed content, confirming it is the presentation itself, not just an announcement of it.
2008-11-27 English
Results of Annual General Meeting 1 page ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF ANNUAL GENERAL MEETING' and provides detailed voting results for resolutions passed at the AGM held on 28 November 2008. It includes vote counts for each resolution, such as remuneration report approval, director re-election, ratification of incentive options, and auditor appointment. The document is short (1376 characters) and focuses solely on the official voting outcomes of the AGM, not the full AGM materials or presentations. Therefore, it fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2008-11-27 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'SHAREHOLDER UPDATE OCTOBER 2008' and contains detailed operational updates on vaccine development, trial results, and regulatory interactions. It includes a section titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' which is a standard quarterly cash flow and financial activity report under ASX rules. The document contains actual financial data such as cash flows, payments to directors, and financing facilities, indicating it is a substantive financial report for a quarter ending 30 September 2008. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a brief summary but includes comprehensive financial data and operational updates for the quarter. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2008
2008-10-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.